• DOI:10.1517/14656560802532707
Corpus ID: 71240383

Pimavanserin tartrate: a 5-HT2A inverse agonist with potential for treating various neuropsychiatric disorders

@article{Abbas2008PimavanserinTA,
  title={Pimavanserin tartrate: a 5-HT2A inverse agonist with potential for treating various neuropsychiatric disorders},
  author={A. Abbas and B. Roth},
  journal={Expert Opinion on Pharmacotherapy},
  year={2008},
  volume={9},
  pages={3251 - 3259}
}

• A. Abbas, B. Roth
• Published 2008
• Medicine
• Expert Opinion on Pharmacotherapy

Background: Pimavanserin tartrate is the first 5-HT2A inverse agonist to enter clinical trials as a treatment for L-dopa-induced psychosis in Parkinson's disease and for augmentation of low-dose risperidone treatment in schizophrenia. Pimavanserin is also being evaluated as a possible anti-insomnia drug. Objective: To discuss the potential of pimavanserin to fill multiple therapeutic needs. Methods: The problems with currently approved antipsychotics and sleep agents are explored to highlight… Expand

View on Taylor & Francis

zenodo.org

Save to Library

Create Alert

Cite

Launch Research Feed